Rocket Pharmaceuticals, Inc. (RCKT)

21.86 -1.00 (-4.37%) At close: 04:00PM EDT

Rocket Pharmaceuticals, Inc.

9 Cedarbrook Drive
Cranbury, NJ 08512
United States
609 659 8001
https://www.rocketpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 268

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Gaurav D. Shah M.D.	CEO & Director	1.01M	N/A	1975
Ms. Kinnari Patel M.B.A., Pharm.D.	Head of R&D, President & COO	846.11k	N/A	1979
Mr. Mayo Pujols	Chief Technical Officer	877.69k	N/A	1969
Mr. Jonathan Schwartz M.D.	Chief Medical & Gene Therapy Officer	657.87k	627.82k	1964
Mr. Aaron Ondrey	Chief Financial Officer	N/A	N/A	1977
Mr. Martin Louis Wilson J.D.	General Counsel, Chief Compliance Officer & Chief Corporate Officer	149.95k	N/A	1976
Kevin Giordano	Director of Corporate Communications	N/A	N/A	N/A
Ms. Isabel Carmona J.D.	Chief People Officer	N/A	N/A	N/A
Dr. Gayatri R. Rao J.D., M.D.	Senior VP of Clinical Safety & Chief Regulatory Officer	N/A	N/A	N/A
Mr. Raj Prabhakar M.B.A.	Chief Business Officer	619.13k	N/A	1974

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Corporate governance

Rocket Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 June 2024 is 7. The pillar scores are Audit: 4; Board: 9; Shareholder rights: 6; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.